Exclusion criteria
vitiligo, tumor, bleeding, malignancy, non-melanoma skin cancer, allergy, Crohn’s disease, psychiatric, autoimmune disease, toxicity, ischemia, psoriasis, hemoptysis, rest limb claudication or, comorbidity, gastritis, infection, hypotension, peptic ulcer disease, lentigo maligna, hypersensitivity, myocardial infarction, Grave’s disease, intercurrent illness, hearing loss, tumors
VITILIGO, THIRD DEGREE HEART BLOCK, TUMOR, RECURRENCE, BLEEDING, CARDIOVASCULAR DISEASE, INFLAMMATORY BOWEL DISEASE, SYMPTOMATIC CONGESTIVE HEART FAILURE, ALLERGY, CARDIAC ARRHYTHMIA, LUNG METASTASES, CARCINOMA IN SITU, AUTOIMMUNE DISEASE, MOBITZ II, ISCHEMIA, PSORIASIS, GASTRITIS, BRAIN METASTASES, ULCERATIVE, INFECTION, ADVERSE EVENT, HEPATITIS C, LENTIGO MALIGNA, PEPTIC ULCER DISEASE, CHRONIC HEPATITIS, HYPERSENSITIVITY, METASTASES, UNCONTROLLED HYPERTENSION, MYOCARDIAL INFARCTION, UNSTABLE ANGINA PECTORIS, DISEASE, CERVICAL CANCER, HEARING LOSS, TUMORS

Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Previous enrollment in the present study.Participation in another clinical study with an investigational product during the last 4 weeksAny previous treatment with a PD-1 or PD-L1/CTLA-4 inhibitor, including durvalumab or tremelimumabHistory of another malignancy within the five previous years with low potential risk for recurrence other than:Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of diseaseAdequately treated carcinoma in situ without evidence of disease (for example, cervical cancer in situ)Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 d before the first dose of study drug (14 d before the first dose of study drug for patients who have received prior tyrosine kinase inhibitors (TKIs) (for example, erlotinib, gefitinib and crizotinib)) and within 6 weeks for nitrosourea or mitomycin C. (If sufficient wash-out time has not occurred due to the schedule or pharmacokinetics properties of an agent, a longer wash-out period may be required.)Mean QT interval corrected for heart rate (QTc) ≥ 470 ms calculated from three electrocardiograms (ECGs) using Frediricia’s correctionCurrent or prior use of immunosuppressive medication within 28 d before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg per day of prednisone or an equivalent corticosteroidAny history of hypersensitivity to durvalumab or tremelimumab, FOLFOX or their excipientsAny unresolved toxicity (CTCAE grade >1) from previous anti-cancer therapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (for example, hearing loss and peripherally neuropathy).Any prior grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent or any unresolved grade >1 irAEActive or prior documented autoimmune disease within the past 2 years. Note: Patients with vitiligo, Grave’s disease or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.Active or prior documented inflammatory bowel disease (for example, Crohn’s disease and ulcerative colitis)History of primary immunodeficiencyHistory of organ transplant that requires use of immunosuppressiveHistory of allogeneic organ transplantUncontrolled intercurrent illness, including, but not limited to, ongoing or active infection. Clinically significant cardiovascular disease, including myocardial infarction within 6 months; symptomatic congestive heart failure; uncontrolled hypertension; unstable angina pectoris; cardiac arrhythmia; history of Mobitz II second degree or third degree heart block without a permanent pacemaker in place; hypotension; rest limb claudication or ischemia within 6 months; active peptic ulcer disease or gastritis; active bleeding diatheses, including any patient known to have evidence of acute or chronic hepatitis B, hepatitis C or HIV; or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent.Severe concurrent disease or comorbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollmentOngoing treatment with CYP3A4 substrates or regular taking of grapefruit juiceKnown history of active tuberculosisHistory of leptomeningeal carcinomatosisBrain metastases or spinal cord compressionReceipt of live attenuated vaccination within 30 d before study entry or within 30 d of receiving durvalumabFemale patients who are pregnant or breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlAny condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study resultsSymptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of, but not limited to, surgery, radiation and/or corticosteroidsPatients with uncontrolled seizuresPatients under guardianship, curatorship or judicial protectionKnown allergy or hypersensitivity to investigational product or any excipientPatients with tumors that invade major vessels, as shown unequivocally by imaging studiesPatients with central lung metastases (that is, within 2 cm from the hilum) that are cavitary, as shown unequivocally by imaging studiesPatients with any prior history of bleeding related to the current CRCPatients with a history of gross hemoptysis (bright red blood of ½ teaspoon or more per episode of coughing) ≤3 months before enrollmentPatients with a recurrence delay less than 6 months after the adjuvant chemotherapyPatients with resecable disease